Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Gene Variant Descriptions||FGFR2 rearrangement indicates an unspecified rearrangement of the FGFR2 gene.|
|Associated Drug Resistance|
|Category Variants Paths||
FGFR2 mutant FGFR2 rearrange
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 rearrange||cholangiocarcinoma||sensitive||Futibatinib||Phase I||Actionable||In a Phase I trial, Lytgobi (futibatinib) treatment resulted in partial response in 2 patients with cholangiocarcinoma harboring FGFR2 rearrangements (Annals of Oncology, Volume 29, Issue suppl_5).||detail...|
|FGFR2 rearrange||cholangiocarcinoma||sensitive||Futibatinib||Guideline||Actionable||Lytgobi (futibatinib) is included in guidelines as subsequent-line therapy (category 2A) for patients with cholangiocarcinoma harboring an FGFR2 fusion or rearrangement (NCCN.org).||detail...|
|FGFR2 rearrange||cholangiocarcinoma||sensitive||Pemigatinib||FDA approved - On Companion Diagnostic||Actionable||In a Phase II (FIGHT-202) trial, Pemazyre (pemigatinib) treatment resulted in an objective response in 35.5% (38/107, 3 complete response, 35 partial response) of patients with advanced cholangiocarcinoma harboring FGFR2 fusions or rearrangements, with a disease control rate of 82% (88/107), median time-to-response of 2.7 months, and a median progression-free survival of 6.9 months (PMID: 32203698; NCT02924376).||detail... 32203698 detail...|
|FGFR2 rearrange||cholangiocarcinoma||sensitive||Pemigatinib||Guideline||Actionable||Pemazyre (pemigatinib) is included in guidelines as subsequent-line therapy for patients with cholangiocarcinoma harboring FGFR2 fusions or rearrangements (NCCN.org).||detail...|
|FGFR2 rearrange||intrahepatic cholangiocarcinoma||sensitive||Futibatinib||FDA approved||Actionable||In a Phase II trial (FOENIX-CCA2) that supported FDA approval, Lytgobi (futibatinib) demonstrated safety and resulted in an objective response rate of 42% (43/103, 1 complete response, 42 partial responses), disease control rate of 83% (85/103), median duration of response of 9.7 mo, median progression-free survival of 9.0 mo, and median overall survival of 21.7 mo in patients with advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements (PMID: 36652354; NCT02052778).||detail... 36652354|
|FGFR2 rearrange||cholangiocarcinoma||sensitive||Infigratinib||FDA approved - On Companion Diagnostic||Actionable||In a Phase II trial that supported FDA approval, Truseltiq (infigratinib) treatment demonstrated manageable toxicity, resulted in an objective response rate of 23.1% (25/108, 1 complete response, 24 partial responses) in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 fusion or rearrangement, with a median duration of response of 5.0 months and a median progression-free survival of 7.3 months (J Clin Oncol 39, no. 3_suppl (January 20, 2021) 265-265; NCT02150967).||detail... detail... detail...|
|FGFR2 rearrange||cholangiocarcinoma||sensitive||Infigratinib||Guideline||Actionable||Truseltiq (infigratinib) is included in guidelines as a subsequent-line therapy for patients with cholangiocarcinoma harboring an FGFR2 fusion or rearrangement (NCCN.org).||detail...|
|FGFR2 rearrange||pancreatic ductal adenocarcinoma||predicted - sensitive||Erdafitinib||Case Reports/Case Series||Actionable||In a clinical case study, Balversa (erdafitinib) treatment resulted in decrease in the pulmonary lesions, symptom improvement, and decreased CA 19-9 levels with treatment continuing at least 12 months in a patient with pancreatic ductal adenocarcinoma harboring an FGFR2 rearrangement (PMID: 36240849).||36240849|